Valsts: Malaizija
Valoda: angļu
Klimata pārmaiņas: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
TIMOLOL MALEATE
AIN MEDICARE SDN. BHD.
TIMOLOL MALEATE
5ml ml
AIN MEDICARE SDN. BHD.
USER INFORMATION TIMOLAIN TIMOLOL MALEATE OPHTHALMIC SOLUTION USP (TIMOLOL 0.5%) PRODUCT DESCRIPTION: Timolol Maleate Ophthalmic Solution is a sterile, aqueous solution of Timolol Maleate. The solution is a clear and colourless to light yellow solution. Each mL solution contains Timolol 5mg corresponding to 6.8mg of Timolol Maleate and Benzalkonium Chloride 0.01% w/v as preservative. PHARMACODYNAMICS: Timolol Maleate is a non-selective beta-adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anaesthetic activity. Timolol Maleate combines reversibly with the beta-adrenergic receptor, and this inhibits the usual biologic response that would occur with stimulation of that receptor. This specific competitive antagonism blocks stimulation of the beta-adrenergic stimulating (agonist) activity, whether these originate from an endogenous or exogenous source. Reversal of this blockade can be accomplished by increasing the concentration of the agonist which will restore the usual biological response. Unlike miotics, TIMOLAIN reduces IOP with little or no effect on accommodation or pupil size. In patients with cataracts, the inability to see around lenticular opacities when the pupil is constricted is avoided. When changing patients from miotics to TIMOLAIN; a refraction might be necessary when the effects of the miotic have passed. _Paediatric _ _Population:_ There is only very limited data available on the use of Timolol in the paediatric population. PHARMACOKINETICS: The onset of reduction in intra-ocular pressure can be detected within one-half hour after a single dose. The maximum effect occurs in one or two hours; significant lowering of IOP can be maintained for as long as 24 hours with a single dose. _Paediatric Population:_ As already confirmed by adult data, 80% of each eye drop passes through the nasolacrimal system where it may be rapidly absorbed into the systemic circulation via the nasal mucosa, conjunctiva, nasolacrimal du Izlasiet visu dokumentu